Li Sijian, Wang Xiaoxue, Hong Ruping, Zhang Xinyue, Yin Min, Zhang Tianyu, Yang Jiaxin
National Clinical Research Center for Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.
Diagnostics (Basel). 2023 Apr 28;13(9):1581. doi: 10.3390/diagnostics13091581.
Benign struma ovarii (SO) has a probability of metastasis named "peritoneal strumosis", which is extremely rare, such that the specific clinical characteristics, treatment options, and survival outcomes remain unclear. We screened three cases of peritoneal strumosis among 229 cases of SO treated in our hospital. Case 1 was a 36-year-old woman with extensive peritoneal seedings at initial presentation. The second one was a 49-year-old with trocar site implant 11 years after laparoscopic adnexectomy. Case 3 was a 45-year-old woman who had an isolated lesion at the anterior surface of the rectum after laparoscopic ovarian cystectomy for SO 14 years ago. These three patients underwent surgery without any adjuvant treatment and remained disease-free after 30 to 68 months. A systematic review was then conducted and another 16 cases were identified. More than half (10/19, 52.6%) of the patients had previous SO-related ovarian surgery. The median interval between prior SO-related surgery and the initial presentation of peritoneal strumosis was 10.0 years; both regional and distant metastasis, even in the liver, lung, and heart, could also be affected. Surgery was the mainstay therapy (18/19, 94.7%), in which six patients (6/19, 31.7%) were treated with total thyroidectomy (TT) followed by radioiodine (RAI) therapy. Postoperative chemotherapy was only applied in one patient, and the last one only received a diagnostic biopsy without further treatment. Recurrence was noted in two patients with a median recurrence-free survival of 12 years, where surgical excision and RAI were then performed. No death occurred after a mean follow-up of 53 months, where 12 patients achieved no evidence of disease and five were alive with the disease. Peritoneal strumosis has unpredictable biological behaviors and the crude incidence is approximately 1.3% in SO. Patients with peritoneal strumosis have excellent survival outcomes, irrespective of different treatment strategies employed. Surgery with personalized RAI should be preferred and long-term close monitoring is recommended.
良性卵巢甲状腺肿(SO)存在一种名为“腹膜甲状腺肿病”的转移可能性,极为罕见,以至于其具体临床特征、治疗方案及生存结局仍不明确。我们在我院治疗的229例SO病例中筛查出3例腹膜甲状腺肿病。病例1是一名36岁女性,初诊时已有广泛腹膜播散。病例2是一名49岁女性,在腹腔镜附件切除术后11年出现套管针穿刺部位种植。病例3是一名45岁女性,14年前因SO行腹腔镜卵巢囊肿切除术后,在直肠前表面出现孤立性病变。这3例患者均接受了手术,未进行任何辅助治疗,术后30至68个月无疾病复发。随后进行了一项系统综述,又识别出16例病例。超过半数(10/19,52.6%)的患者既往有与SO相关的卵巢手术史。既往SO相关手术与腹膜甲状腺肿病初诊之间的中位间隔时间为10.0年;区域和远处转移,甚至肝脏、肺和心脏也可能受累。手术是主要治疗手段(18/19,94.7%),其中6例患者(6/19,31.7%)接受了全甲状腺切除术(TT),随后进行放射性碘(RAI)治疗。仅1例患者术后接受了化疗,另1例仅接受了诊断性活检,未进一步治疗。2例患者出现复发,无复发生存期的中位时间为12年,随后进行了手术切除和RAI治疗。平均随访53个月后无死亡病例,12例患者无疾病证据,5例患者带瘤生存。腹膜甲状腺肿病具有不可预测的生物学行为,在SO中的粗发病率约为1.3%。无论采用何种不同治疗策略,腹膜甲状腺肿病患者的生存结局都很好。应首选个体化RAI手术治疗,并建议长期密切监测。